What You Ought to Know:
– Viome Life Sciences, a mission-driven digital health firm, introduced extra $67M in funding towards its Collection C spherical.
– Led by Daring Capital Group, the $67M increase brings the corporate’s complete funding to over $150M and will probably be used to assist the event of its at-home exams that leverage precision diet to enhance well being and improve longevity by addressing the epidemic of continual ailments, cancers, and ageing.
– Viome will develop its proprietary mRNA sequencing expertise and AI-powered platform that was awarded FDA Breakthrough Gadget Designation standing, to debut a collection of latest wellness and diagnostic exams particularly focusing on the oral microbiome which has a robust connection to systemic ailments. This may embrace hard-to-detect cancers and GI issues resembling IBD.
– The funding announcement comes off the heels of Viome’s first CancerDetect™ test, a revolutionary early diagnostic device that may detect not simply stage 1 however early biomarkers related to oral and throat most cancers with unprecedented charges of 95% specificity and 90% sensitivity.
